Evidence map›Paper›PMID 38847198›Full record

ArticleHuman vaccines & immunotherapeutics2024

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.

Martine C Maculaitis, Brett Hauber, Kathleen M Beusterien, Oliver Will, Lewis Kopenhafer, Amy W Law, Jeffrey T Vietri, Joseph C Cappelleri, Joshua R Coulter, Sarah Pugh and 1 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Martine C MaculaitisReal World Data & Analytics, Oracle Life Sciences, Austin, TX, USA.
Brett HauberWorldwide Medical and Safety, Pfizer Inc, New York, NY, USA.
Kathleen M BeusterienReal World Data & Analytics, Oracle Life Sciences, Austin, TX, USA.
Oliver WillReal World Data & Analytics, Oracle Life Sciences, Austin, TX, USA.
Lewis KopenhaferReal World Data & Analytics, Oracle Life Sciences, Austin, TX, USA.
Amy W LawGlobal Access & Value Pfizer Inc, New York, NY, USA.
Jeffrey T VietriGlobal Access & Value, Pfizer Inc, Collegeville, PA, USA.
Joseph C CappelleriStatistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA.
Joshua R CoulterWorldwide Medical and Safety, Pfizer Inc, New York, NY, USA.
Sarah PughUS Vaccines Medical & Scientific Affairs, Pfizer Inc, New York, NY, USA.
Kimberly M SheaGlobal Access & Value Pfizer Inc, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A maternal vaccine and long-acting monoclonal antibody (mAb) were recently approved to protect infants against respiratory syncytial virus (RSV). We identified subgroups of pregnant people with different preferences for RSV preventives and respondent characteristics associated with subgroup membership. An online survey, including a discrete choice experiment (DCE), was conducted among US pregnant people. RSV preventive attributes included effectiveness, duration of protection during RSV season, injection recipient/timing, preventive type (vaccine or mAb), and type of visit required to receive injection. In DCE choice tasks, pregnant people selected between two hypothetical preventive profiles with varying attribute-levels and a no-preventive option. Logistic regression, including latent class analysis (LCA), was used to analyze the data. Of 992 pregnant people (mean age: 30.0 years), 60.3% were expecting their second/later birth. LCA identified three preference subgroups: 'Effectiveness' (preventive choice mostly driven by increases in effectiveness; 51.4% class membership probability), 'Season' (preventive choice mostly driven by improvement in duration of protection during the RSV season; 39.2% class membership probability), and 'No Preventive' (frequently chose no-preventive option; 9.4% class membership probability). 'Effectiveness' and 'Season' preferred maternal vaccine over mAb; mAb was preferred by 'No Preventive.' Perceiving RSV as serious for infants, higher health literacy, and lower household income were associated with 'Effectiveness.' Perceiving RSV as serious for pregnant people was associated with 'Season.' Perceiving RSV to not be serious for pregnant people and not being employed were associated with 'No Preventive.' Subgroups of pregnant people vary in preferences for RSV preventives. Most pregnant people preferred a maternal vaccine, although some may be more willing to accept alternative preventive options.

Indexed as

Latent Class AnalysisRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdolescentAdultAntibodies, MonoclonalFemaleHumansInfantPatient PreferencePregnancyPregnant PeopleSurveys and QuestionnairesUnited StatesVaccinationAntibodies, MonoclonalRespiratory Syncytial Virus VaccinesMaternal vaccinationmonoclonal antibodiespreference heterogeneitypreferencespregnant peoplerespiratory syncytial virus

Identifiers

PMID38847198
PMCPMC11164215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.